The DOI matches its Crossref record.
P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most patients with multiple myeloma have a relapse after standard treatment, and outcomes worsen with each subsequent line of therapy.
“outcomes worsen with each subsequent line of therapy. 3-5”
From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationTouzeau, C., Lipe, B., Khan, A., Dhakal, B., Nair, S., He, J.-M., Mendes, J., Lee, S. P., Lonardi, C., Slaughter, A. R., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03308-2 · Cited by 2
Self-citationDhakal, B. (2024) · The Hematologist · doi:10.1182/hem.v21.3.202432 · Cited by 1
Self-citation
Metadata
- Authors
- Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., Voelker, J., Cost, P., Valluri, S., Yalniz, F., Pacaud, L., & Yong, K.
- ORCID
- Venue
- Clinical Lymphoma Myeloma and Leukemia
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 22
- Pages
- S167
- ISSN
- 2152-2650 (ISSN-L)
- OpenAlex
- W4293107848
- Cited by
- 3
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Clinical Lymphoma Myeloma & Leukemia (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- relapsed multiple myeloma, lenalidomide-refractory disease, treatment patterns, treatment outcomes, SEER-Medicare, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
